Primary Care Diabetes
Volume 1, Issue 4 , Pages 209-211 , December 2007

New treatments for type 2 diabetes—The DPP4 inhibitors

  • Roger Gadsby

      Affiliations

    • Corresponding Author InformationTel.: +44 2476 573101; fax: +44 2476 573959.

Received 14 October 2007 ,Accepted 15 October 2007.

References 

  1. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care. 2006;29:435–449
  2. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes systematic review and meta-analysis. JAMA. 2007;298:194–206
  3. Ahren B. Dipeptidyl peptidase-4 inhibitors clinical data and clinical implications. Diabetes Care. 2007;30:1344–1350
  4. C.J. Rosen, The rosiglitazone story—lessons from a FDA advisory committee meeting, N. Engl. J. Med., published at www.nejm.org.am on August 8th, 2007, accessed on August 14th, 2007.

PII: S1751-9918(07)00111-8

doi: 10.1016/j.pcd.2007.10.004

Primary Care Diabetes
Volume 1, Issue 4 , Pages 209-211 , December 2007

Article Tools